NO326303B1 - Anvendelse av VEGF protein for behandling av intimal hyperplasi - Google Patents
Anvendelse av VEGF protein for behandling av intimal hyperplasi Download PDFInfo
- Publication number
- NO326303B1 NO326303B1 NO19992106A NO992106A NO326303B1 NO 326303 B1 NO326303 B1 NO 326303B1 NO 19992106 A NO19992106 A NO 19992106A NO 992106 A NO992106 A NO 992106A NO 326303 B1 NO326303 B1 NO 326303B1
- Authority
- NO
- Norway
- Prior art keywords
- vegf
- protein
- treatment
- blood vessel
- cells
- Prior art date
Links
- 206010020718 hyperplasia Diseases 0.000 title claims abstract description 50
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title claims description 282
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title claims description 277
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 38
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
- 230000002265 prevention Effects 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 104
- 210000001367 artery Anatomy 0.000 claims description 60
- 150000007523 nucleic acids Chemical class 0.000 claims description 55
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 210000002889 endothelial cell Anatomy 0.000 claims description 30
- 210000002808 connective tissue Anatomy 0.000 claims description 22
- 238000001356 surgical procedure Methods 0.000 claims description 22
- 210000003038 endothelium Anatomy 0.000 claims description 20
- 239000013603 viral vector Substances 0.000 claims description 15
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 14
- 230000036262 stenosis Effects 0.000 claims description 14
- 208000037804 stenosis Diseases 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 12
- 238000002399 angioplasty Methods 0.000 claims description 11
- 208000037803 restenosis Diseases 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 230000003872 anastomosis Effects 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 238000011477 surgical intervention Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 210000001147 pulmonary artery Anatomy 0.000 claims description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 58
- 229960001123 epoprostenol Drugs 0.000 abstract description 9
- 239000007943 implant Substances 0.000 abstract description 6
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 abstract 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 280
- 230000000694 effects Effects 0.000 description 86
- 230000015572 biosynthetic process Effects 0.000 description 70
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 60
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 56
- 238000012546 transfer Methods 0.000 description 54
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 53
- 102100037611 Lysophospholipase Human genes 0.000 description 46
- 108020002496 Lysophospholipase Proteins 0.000 description 45
- 150000001413 amino acids Chemical class 0.000 description 39
- 235000018102 proteins Nutrition 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 31
- 229940024606 amino acid Drugs 0.000 description 31
- 229940114079 arachidonic acid Drugs 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 30
- 102000043136 MAP kinase family Human genes 0.000 description 29
- 108091054455 MAP kinase family Proteins 0.000 description 29
- 239000000556 agonist Substances 0.000 description 28
- 235000021342 arachidonic acid Nutrition 0.000 description 28
- 241001430294 unidentified retrovirus Species 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 26
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 25
- 102100035194 Placenta growth factor Human genes 0.000 description 25
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 22
- 239000002502 liposome Substances 0.000 description 22
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 22
- 239000013598 vector Substances 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 241000701161 unidentified adenovirus Species 0.000 description 20
- 108090000190 Thrombin Proteins 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- 229960004072 thrombin Drugs 0.000 description 19
- 229960001134 von willebrand factor Drugs 0.000 description 19
- 108010047303 von Willebrand Factor Proteins 0.000 description 18
- 102100036537 von Willebrand factor Human genes 0.000 description 18
- 239000002609 medium Substances 0.000 description 16
- 241000700605 Viruses Species 0.000 description 15
- 230000001419 dependent effect Effects 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 101150066555 lacZ gene Proteins 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 14
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 12
- 210000001715 carotid artery Anatomy 0.000 description 12
- 102000058223 human VEGFA Human genes 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 10
- 230000002950 deficient Effects 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 241000713869 Moloney murine leukemia virus Species 0.000 description 9
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 9
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 108010005774 beta-Galactosidase Proteins 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 102100026189 Beta-galactosidase Human genes 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 108091008605 VEGF receptors Proteins 0.000 description 6
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 5
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 5
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000008719 thickening Effects 0.000 description 5
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 4
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 4
- 206010029113 Neovascularisation Diseases 0.000 description 4
- -1 OCT compound Chemical class 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000011587 new zealand white rabbit Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 3
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000239218 Limulus Species 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 229940122985 Peptide agonist Drugs 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- 102100026918 Phospholipase A2 Human genes 0.000 description 2
- 101710096328 Phospholipase A2 Proteins 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 2
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000003881 arterial anastomosis Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- 150000000640 6-keto-prostaglandin F1α derivatives Chemical class 0.000 description 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100263579 Bos taurus VEGFA gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 102000017055 Lipoprotein Lipase Human genes 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 description 1
- 108020002334 Monoacylglycerol lipase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 description 1
- CZSLEMCYYGEGKP-UHFFFAOYSA-N N-(2-chlorobenzyl)-1-(2,5-dimethylphenyl)benzimidazole-5-carboxamide Chemical compound CC1=CC=C(C)C(N2C3=CC=C(C=C3N=C2)C(=O)NCC=2C(=CC=CC=2)Cl)=C1 CZSLEMCYYGEGKP-UHFFFAOYSA-N 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101150093295 Pla2g4a gene Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010071989 Vascular endothelial growth factor overexpression Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960005220 fluanisone Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229950008418 talipexole Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009495 transient activation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
- C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Prostheses (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9622852.3A GB9622852D0 (en) | 1996-11-01 | 1996-11-01 | Treatment of intimal hyperplasma |
| GBGB9709494.0A GB9709494D0 (en) | 1997-05-09 | 1997-05-09 | Delivery device and method |
| GBGB9717791.9A GB9717791D0 (en) | 1997-08-21 | 1997-08-21 | Treatment of intimal hyperplasia |
| PCT/GB1997/003015 WO1998020027A2 (en) | 1996-11-01 | 1997-11-03 | Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO992106D0 NO992106D0 (no) | 1999-04-30 |
| NO992106L NO992106L (no) | 1999-06-30 |
| NO326303B1 true NO326303B1 (no) | 2008-11-03 |
Family
ID=27268562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19992106A NO326303B1 (no) | 1996-11-01 | 1999-04-30 | Anvendelse av VEGF protein for behandling av intimal hyperplasi |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7320679B2 (enExample) |
| EP (2) | EP1488761A1 (enExample) |
| JP (3) | JP2001503755A (enExample) |
| KR (1) | KR100695590B1 (enExample) |
| AT (1) | ATE287271T1 (enExample) |
| AU (1) | AU729420B2 (enExample) |
| CA (1) | CA2270286C (enExample) |
| DE (1) | DE69732304T2 (enExample) |
| ES (1) | ES2235227T3 (enExample) |
| HU (1) | HU223957B1 (enExample) |
| NO (1) | NO326303B1 (enExample) |
| PL (1) | PL189744B1 (enExample) |
| PT (1) | PT941116E (enExample) |
| WO (1) | WO1998020027A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| US20080305999A1 (en) * | 1996-11-01 | 2008-12-11 | John Francis Martin | Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia |
| EP1019082B2 (en) | 1997-10-02 | 2008-06-04 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| GB9809082D0 (en) | 1998-04-28 | 1998-06-24 | Eurogene Limited | Delivery device |
| ATE253934T1 (de) * | 1998-09-09 | 2003-11-15 | Scios Inc | Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien |
| US6596699B2 (en) | 1998-09-22 | 2003-07-22 | Biosurface Engineering Technologies, Inc. | Nucleic acid coating compositions and methods |
| US6958147B1 (en) | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
| FR2792531B1 (fr) * | 1999-04-26 | 2003-01-31 | Aventis Pharma Sa | Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire |
| HUP0200961A3 (en) * | 1999-04-26 | 2004-11-29 | Inst Nat Sante Rech Med | Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension |
| ATE364387T1 (de) * | 1999-09-23 | 2007-07-15 | An Go Gen Inc | Zellbasierte gentherapie für das lungensystem |
| JP2003513105A (ja) * | 1999-11-02 | 2003-04-08 | ジェネンテック・インコーポレーテッド | ｅＮＯＳ活性の調節とその治療的使用 |
| US7078382B1 (en) | 1999-11-02 | 2006-07-18 | Genentech, Inc. | Modulation of eNOS activity and therapeutic uses thereof |
| SE0000285D0 (sv) * | 1999-12-07 | 2000-01-31 | Mika Lahtinen | Medical implant |
| AU3988401A (en) | 2000-02-25 | 2001-09-03 | Ludwig Inst Cancer Res | Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins |
| GB0012997D0 (en) * | 2000-05-26 | 2000-07-19 | Eurogene Limited | Gene delivery |
| WO2002096469A2 (en) * | 2001-05-29 | 2002-12-05 | Ark Therapeutics Ltd. | Gene delivery via a baculovirus vector |
| EP1406559A1 (en) * | 2001-07-06 | 2004-04-14 | Tricardia, L.L.C. | Anti-arrhythmia devices and methods of use |
| SE0102578L (sv) * | 2001-07-20 | 2003-01-21 | Oeyvind Reitan | Förändring av en stents egenskaper för att förhindra restenos |
| CA2526643A1 (en) * | 2003-06-18 | 2004-12-29 | Georg-August-Universitat Gottingen | Use of a vegf receptor gene or gene product |
| GB0515140D0 (en) * | 2005-07-22 | 2005-08-31 | Ark Therapeutics Ltd | Therapeutic device |
| ES2363758T3 (es) | 2005-08-15 | 2011-08-16 | Vegenics Pty Ltd | Vegf y pdgf modificados con propiedades angiogénicas mejoradas. |
| JP2009523807A (ja) * | 2006-01-18 | 2009-06-25 | ザ ジェネラル ホスピタル コーポレイション | リンパ機能を高める方法 |
| US8721711B2 (en) | 2007-06-20 | 2014-05-13 | Oregon Health & Science University | Graft having microporous membrane for uniform fluid infusion |
| CA2746807A1 (en) * | 2007-12-14 | 2009-06-25 | Oregon Health & Science University | Drug delivery cuff |
| DE102008002396A1 (de) * | 2008-06-12 | 2009-12-17 | Biotronik Vi Patent Ag | Implantierbares Wirkstoffreservoir und Vorrichtung mit einem implantierbaren Wirkstoffreservoir |
| JP6562632B2 (ja) * | 2012-02-14 | 2019-08-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現 |
| WO2013135266A1 (en) | 2012-03-12 | 2013-09-19 | Gemvax As | Treatment of non-small cell lung carcinoma by active immunotherapy |
| CN104684561A (zh) | 2012-08-01 | 2015-06-03 | 联合治疗公司 | 利用间充质干细胞的肺动脉高血压的治疗 |
| KR102466885B1 (ko) | 2013-01-09 | 2022-11-11 | 유나이티드 세러퓨틱스 코오포레이션 | 프로스타시클린 및 중간엽 줄기 세포를 사용한 혈관병증의 치료 |
| JP7179723B2 (ja) | 2016-10-24 | 2022-11-29 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルによるｍｓｃの免疫調節特性の増強 |
| CN114040923B (zh) * | 2019-04-05 | 2024-11-26 | 韩国窑业技术院 | 利用肌集钙蛋白标签的蛋白质的表达及纯化方法 |
| IT201900012537A1 (it) * | 2019-07-22 | 2021-01-22 | Milano Politecnico | Dispositivo di condizionamento per condizionare un tratto esposto di un vaso sanguigno e metodo |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797485A (en) * | 1971-03-26 | 1974-03-19 | Alza Corp | Novel drug delivery device for administering drug into blood circulation in blood vessel |
| JPS56122317A (en) * | 1980-02-29 | 1981-09-25 | Koken:Kk | Drug transporting material and its preparation |
| US5326568A (en) * | 1991-05-03 | 1994-07-05 | Giampapa Vincent C | Method of tissue-specific delivery |
| US5201728A (en) * | 1991-05-03 | 1993-04-13 | Giampapa Vincent C | Subcutaneous implantable multiple-agent delivery system |
| US5399352A (en) * | 1993-04-14 | 1995-03-21 | Emory University | Device for local drug delivery and methods for using the same |
| EP0702518B1 (en) * | 1993-06-11 | 2003-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
| US5653744A (en) * | 1995-04-27 | 1997-08-05 | Khouri Biomedical Research, Inc. | Device and method for vascular anastomosis |
| US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
-
1997
- 1997-11-03 AU AU47906/97A patent/AU729420B2/en not_active Ceased
- 1997-11-03 EP EP04021613A patent/EP1488761A1/en not_active Withdrawn
- 1997-11-03 ES ES97910563T patent/ES2235227T3/es not_active Expired - Lifetime
- 1997-11-03 HU HU9902867A patent/HU223957B1/hu not_active IP Right Cessation
- 1997-11-03 PL PL97333272A patent/PL189744B1/pl not_active IP Right Cessation
- 1997-11-03 AT AT97910563T patent/ATE287271T1/de active
- 1997-11-03 CA CA002270286A patent/CA2270286C/en not_active Expired - Fee Related
- 1997-11-03 DE DE69732304T patent/DE69732304T2/de not_active Expired - Lifetime
- 1997-11-03 KR KR1019997003881A patent/KR100695590B1/ko not_active Expired - Fee Related
- 1997-11-03 EP EP97910563A patent/EP0941116B1/en not_active Expired - Lifetime
- 1997-11-03 PT PT97910563T patent/PT941116E/pt unknown
- 1997-11-03 JP JP52114098A patent/JP2001503755A/ja not_active Withdrawn
- 1997-11-03 WO PCT/GB1997/003015 patent/WO1998020027A2/en not_active Ceased
-
1999
- 1999-04-30 NO NO19992106A patent/NO326303B1/no not_active IP Right Cessation
-
2003
- 2003-02-19 US US10/370,291 patent/US7320679B2/en not_active Expired - Fee Related
-
2008
- 2008-01-11 JP JP2008004349A patent/JP4783797B2/ja not_active Expired - Fee Related
-
2011
- 2011-10-27 JP JP2011236266A patent/JP2012031196A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2270286A1 (en) | 1998-05-14 |
| PL189744B1 (pl) | 2005-09-30 |
| US20030225020A1 (en) | 2003-12-04 |
| EP0941116B1 (en) | 2005-01-19 |
| JP2008155036A (ja) | 2008-07-10 |
| HUP9902867A3 (en) | 2001-12-28 |
| PL333272A1 (en) | 1999-11-22 |
| HUP9902867A2 (hu) | 1999-12-28 |
| WO1998020027A2 (en) | 1998-05-14 |
| AU4790697A (en) | 1998-05-29 |
| DE69732304D1 (de) | 2005-02-24 |
| ATE287271T1 (de) | 2005-02-15 |
| WO1998020027A3 (en) | 1998-10-08 |
| JP4783797B2 (ja) | 2011-09-28 |
| JP2012031196A (ja) | 2012-02-16 |
| US7320679B2 (en) | 2008-01-22 |
| PT941116E (pt) | 2005-05-31 |
| NO992106D0 (no) | 1999-04-30 |
| KR20000052999A (ko) | 2000-08-25 |
| AU729420B2 (en) | 2001-02-01 |
| EP1488761A1 (en) | 2004-12-22 |
| EP0941116A2 (en) | 1999-09-15 |
| DE69732304T2 (de) | 2005-06-02 |
| CA2270286C (en) | 2009-03-03 |
| NO992106L (no) | 1999-06-30 |
| ES2235227T3 (es) | 2005-07-01 |
| HU223957B1 (hu) | 2005-03-29 |
| KR100695590B1 (ko) | 2007-03-14 |
| JP2001503755A (ja) | 2001-03-21 |
| HK1108845A1 (zh) | 2008-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2270286C (en) | Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device | |
| US5851521A (en) | Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis | |
| US6203991B1 (en) | Inhibition of smooth muscle cell migration by heme oxygenase I | |
| EP0892644B1 (en) | In vivo gene transfer methods for wound healing | |
| US20060275338A1 (en) | Drug-eluting intravascular prostheses and methods of use | |
| JPH10501989A (ja) | 疾患治療用誘導型一酸化窒素シンターゼ遺伝子 | |
| US20120308522A1 (en) | Therapeutic Use of Growth Factor, and Delivery Device, Especially for the Treatment of Intimal Hyperplasia | |
| US7247618B2 (en) | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling | |
| EP1307582B1 (en) | Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis | |
| EP1984040A1 (en) | Drug-eluting intravascular prostheses and methods of use | |
| FI120154B (fi) | Yhdistelmä-DNA-viruksia, niitä sisältävä farmaseuttinen koostumus, niillä tartutettu nisäkässolu ja soluja sisältävä istute | |
| MXPA99004088A (en) | Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia | |
| HK1108845B (en) | Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device | |
| CN1264570C (zh) | 生长因子vegf在制备治疗或预防血管内膜增生的药物中的用途 | |
| WO2007089780A2 (en) | Bmx/etk tyrosine kinase gene therapy materials and methods | |
| Van-Assche et al. | Gene delivery strategies targeting stable atheromatous plaque | |
| US20090285791A1 (en) | Regenerating and enhancing development of muscle tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |